WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 ...

Until recently, the choice of full-service outsourcing (FSO) vs functional service partnerships (FSP) most frequently was ...

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...

Enterprises around the world are turning to Microsoft's AI and cloud ecosystem to support projects that will help them navigate unpredictable markets, according to a new research report published ...

Blueprint Medicines Corporation today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, in Las Vegas, Nevada, was host to the Plenary Session on Saturday. Dr. Samir Taneja gave the State-of-the-Art Lecture titled: ...

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to ...

Physician's Weekly has developed an innovative, peer-led initiative designed to transform the way oncologists engage with ...

In the phase III SELECT-GCA trial ... autoimmune rheumatic diseases are more prevalent in women than men, few clinical trials report findings on the basis of sex and gender.

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion ...

Artificial intelligence (AI) has the potential to reshape the pharmaceutical industry, potentially cutting drug development time by up to 70% and reducing the number of clinical trial phases ...